Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator ...

Pharmacies will be the canary in the coal mine for the Medicare Drug Price Negotiation Program, writes Sujith Ramachandran.

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm ...

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...

Pharmacy benefit managers (PBMs) are back in the crosshairs. PBMs negotiate drug prices down on behalf of consumers and insurers – to the ire of ...

Spain’s pharma sector is a hub for clinical trials, exports and digital innovation, but access and value-based reforms remain ...

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...

Beginning Jan. 1, 2026, Optum Rx, the pharmacy benefit manager of UnitedHealthcare, will reduce reauthorizations for an ...

Telehealth is making it easier for people to access GLP-1 medications, but insurance coverage and understanding those rules are still big hurdles for many patients in 2025. New tech and personalized ...